Blueprint Medicines (BPMC) PT Lowered to $113 at Wedbush

Go back to Blueprint Medicines (BPMC) PT Lowered to $113 at Wedbush

UPDATE: Deutsche Bank Downgrades Blueprint Medicines (BPMC) to Hold

October 28, 2019 12:19 PM EDT

(Updated - October 28, 2019 12:21 PM EDT)

(updated to add analyst comments)

Deutsche Bank analyst Kostantinos Aprilakis downgraded Blueprint Medicines (NASDAQ: BPMC) from Buy to Hold with a price target of $75.00 (from $110).

The analyst commented, "In a surprise announcement this morning, BPMC announced the FDAs... More

Blueprint Medicines (BPMC) Announces FDA Intent to Split Avapritinib NDA into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

October 28, 2019 8:01 AM EDT

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced an update regarding its New Drug Application (NDA) for avapritinib for the treatment of adults with PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and fourth-line GIST.

On October 25, 2019, Blueprint Medicines received written feedback from the U.S. Food and Drug Administration (FDA) following its NDA mid-cycle review meeting. The FDA informed Blueprint Medicines that it intends to administratively split the proposed indications for avapritinib into two separate NDAs, one for PDGFRA... More